December 4-7, 2016

Registration Open

IASLC Lung Cancer News
Issue #3

IASLC Foundation



 Donate Now


We are a global network of specialists working together to conquer lung and thoracic cancers worldwide.

Multidisciplinary Live Learning:

Molecular Testing and Personalized Therapy in Lung Cancer


Featured Science and Communiqués

High-Intensity Interval Training in Patients with Operable NSCLC Improved Aerobic Performance

DENVER – Preoperative high-intensity interval training (HIIT) in patients with resectable non-small cell lung cancer (NSCLC) improved aerobic performance in patients but failed to reduce early complications after tumor resection.

Timing of Surgery after Neoadjuvant Chemoradiation in Stage IIIA NSCLC Impacts Overall Survival

DENVER – The timing of surgery after neoadjuvant chemoradiation in patients with stage IIIA non-small cell lung cancer (NSCLC) affects the overall survival of patients receiving trimodality therapy.

Combined FISH and IHC Identifies Patients with Rare ALK Fusions that Respond to Crizotinib

DENVER – The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment.

Lymph Node Stage May Have Clinical Significance Among NSCLC Patients with Stage IV M1a Disease

DENVER – Analysis of a large non-small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis.